News in Brief

MaSTherCell to make TCR candidates for Zelluna

By Staff Reporter

- Last updated on GMT

GettyImages/selvanegra
GettyImages/selvanegra
Zelluna Immunotherapy has selected MaSTherCell as manufacturing partner for its T-cell receptor (TCR)-based immunotherapies.

Norwegian biopharma firm Zelluna has a number of cancer candidates in early and late stage pre-clinical development, based on its isolated and engineered TCRs.

And to bring these into the clinic, the firm has partnered with Orgenesis subsidiary​ MaSTherCell S.A. to perform process development, optimisation and industrialisation of the current manufacturing process.

“Manufacturing and providing process industrialization from the preclinical ground-level offers significant upside potential for us as the TCR products advance into further stages of clinical development, which Zelluna plans to commence in the 2019,”​ Orgenesis CEO Vered Caplan said in a statement.

Orgenesis bought MaSTherCell and its manufacturing facility in Gosselies, Belgium in 2015 to take control of production of its Type 1 diabetes cell therapy candidate ahead of clinical trials.

Related topics: Bio Developments

Related news

Show more

Follow us

Products

View more

Webinars